Search results for "Anticoagulation"
Pros, cons of prolonged anticoagulation after a clot
Experts debate about provoked vs. unprovoked venous thromboembolism, and whether a once-high-risk patient can have that status removed later.
https://immattersacp.org/archives/2020/02/pros-cons-of-prolonged-anticoagulation-after-a-clot.htm
1 Feb 2020
Aspirin appears to reduce recurrence of VTE after stopping anticoagulants
Aspirin reduced the risk of venous thromboembolism (VTE) recurrence with no apparent increase in major bleeding in patients who had an initial unprovoked VTE and had discontinued anticoagulant treatment, a study found.
https://immattersacp.org/weekly/archives/2012/06/05/6.htm
5 Jun 2012
Use of warfarin down, DOACs up in commercially insured patients with cirrhosis, nonvalvular afib
While more than half of eligible patients with cirrhosis and concurrent nonvalvular atrial fibrillation did not receive anticoagulation between 2012 and 2019, use of direct oral anticoagulants (DOACs) increased substantially during that time, a recent study found.
https://immattersacp.org/weekly/archives/2023/01/17/4.htm
17 Jan 2023
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021
Tailoring anticoagulation more of a reality with DOACs
Direct oral anticoagulants have the potential to replace warfarin for the treatment of many patients with venous thromboembolism, but without a need for routine monitoring, good patient selection is key to their use.
https://immattersacp.org/archives/2018/03/tailoring-anticoagulation-more-of-a-reality-with-doacs.htm
1 Mar 2018
AHA scientific statement offers guidance on LV thrombus
Among other recommendations, clinicians should treat patients with left ventricular (LV) thrombus after myocardial infarction using oral anticoagulants for three months, the American Heart Association (AHA) said.
https://immattersacp.org/weekly/archives/2022/09/20/4.htm
20 Sep 2022
DOACs more effective, cost-effective than LMWH for cancer-associated thrombosis
A meta-analysis compared three direct oral anticoagulants (DOACs) (apixaban, edoxaban, and rivaroxaban) to low-molecular-weight heparin (LMWH) and found that apixaban was usually the most cost-effective option, but that finding hinged on the specific drug price.
https://immattersacp.org/weekly/archives/2023/01/03/5.htm
3 Jan 2023
Risks and benefits of procedure versus medication in afib vary by individual
A modeling study found that left atrial appendage occlusion could be an alternative to oral anticoagulants in patients at high bleeding risk but that the combination of risks for stroke and bleeding should be considered on an individual basis.
https://immattersacp.org/weekly/archives/2022/08/16/4.htm
16 Aug 2022
MKSAP Quiz: Evaluation for easy bruising
A 48-year-old woman is evaluated for easy bruising. She has no history of gingival bleeding, menorrhagia, or bleeding following procedures. Following a physical exam and lab studies, what is the most appropriate diagnostic test?
https://immattersacp.org/weekly/archives/2023/03/28/3.htm
28 Mar 2023
NOACs linked to lower rates of diabetes complications than warfarin in patients with afib and diabetes
A retrospective study from Taiwan found that patients who received non-vitamin K antagonist oral anticoagulants (NOACs) developed fewer macrovascular and microvascular complications, had fewer glycemic emergencies, and were less likely to die than those who received warfarin.
https://immattersacp.org/weekly/archives/2022/02/15/2.htm
15 Feb 2022